

ASX Release

17<sup>th</sup> July 2015

# First Two Canine Patients Complete Combination Therapy with PPL-1

*PharmAust will continue to recruit and treat suitable canine patients*

**PharmAust Limited** (“PharmAust” or “the Company”) (ASX: PAA & PAAO) is pleased to announce that it has completed the treatment of two canine patients with PPL-1 in combination with Carboplatin, one of the “standard of care” chemotherapy drugs used in both human and veterinary anticancer medicine. Neither dog suffered any adverse events despite the fact they both had progressive, advanced cancers and few treatment options. In one of the dogs, the treatment with 5mg/kg PPL-1 in addition to Carboplatin resulted in stable disease for a short period.

PharmAust’s Executive Chairman Dr Roger Aston said “Combining chemotherapy with PPL-1 in a target species with a natural cancer, is an important step for PharmAust. Previous studies in rodents (announced to the market on 17<sup>th</sup> February 2014) showed highly significant synergy between chemotherapy and PPL-1 without enhancement of the associated side-effects commonly seen with anticancer drugs. As such, the lack of any adverse events in canines is an exciting outcome. Furthermore, this gives us much confidence in moving forward with Phase II combination therapies in man”.

Veterinary Oncology Consultants and PharmAust will continue the recruitment and treatment of canine patients with combination therapy in view of the good safety profile seen so far and the possibility that the preliminary effects observed on stabilising progressive cancer in one of the two dogs can be further evaluated.

The US companion pet market sales (est. 2011) are in the region of US\$14 billion whilst cancer therapies are estimated at \$550 million with a price point of around \$1,500 per treatment. PharmAust’s Executive Chairman Dr Roger Aston said “As PPL-1 is already approved for veterinary use by PharmAust’s partner, a major global corporation in the Animal Health Industry, we believe that if successful in this trial, PPL-1 will be able to be approved quickly for the treatment of dog cancers following a further pivotal study”.

**\*References:**

2011-2012 National Pet Owners Survey Gabelli & Company, Inc. 2004. The US Veterinary health market.  
<http://www.vet-dc.com/25.html> American pet products manufacturers association, Inc. 2011-2012 National pet owner’s survey

**For further details please contact:**

**Dr Roger Aston**  
Executive Chairman  
Tel: 0402 762 204  
[rogeraston@pharmaust.com](mailto:rogeraston@pharmaust.com)

**Mr Robert Bishop**  
Executive Director  
Tel: 0417 445 180  
[robertbishop@pharmaust.com](mailto:robertbishop@pharmaust.com)